Prostate Cancer Targeted Therapies Directed to the Androgen-Receptor Signaling Axis as a Model for Drug Development
About Prostate Cancer Targeted Therapies Directed to the Androgen-Receptor Signaling Axis as a Model for Drug Development
Activation of the androgen receptor signaling axis (a network of proteins that respond to androgen stimulus) is responsible for prostate cancer growth and survival. Although there are several anti-androgens available many patients experience remission followed by resistance. Dr. Scher and his team are testing new anti-androgen agents, MDV3100 and Abiraterone, in the laboratory and the clinic to determine combinations of targeted agents likely to have potent anticancer effects. This Challenge Award team will also identify whether circulating tumor cell (CTC; rogue cancer cells that have broken off of the tumor and entered the bloodstream) enumeration and prostate cancer specific PET imaging can predict response to these new agents. Another goal is to develop mouse models of MDV-3100 resistance to understand how patients may become resistant to this medicine. The group plans to test other novel targeted therapies in combination with MDV-3100 and Abiraterone to enhance anti-cancer effects and improve overall survival for patients with advanced prostate cancer.
Research team members: Dr. Charles Sawyers; Memorial Sloan-Kettering Cancer Center, Dr. Neal Rosen; Memorial Sloan-Kettering Cancer Center, and Dr. Steve Larson; Memorial Sloan-Kettering Cancer Center.
Dr. Howard Scher, Memorial Sloan-Kettering Cancer Center